United States securities and exchange commission logo





                          March 22, 2024

       Robert Hershberg
       Chief Executive Officer
       HilleVax, Inc.
       321 Harrison Avenue
       Boston, MA 02118

                                                        Re: HilleVax, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed March 20,
2024
                                                            File No. 333-278110

       Dear Robert Hershberg:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Lauren
Hamill at 303-844-1008 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Cheston Larson